Market Herald logo

Subscribe

Be the first with the news that moves the market
  • This application contributes to Innocan’s expansion of its health and wellness intellectual property portfolio of 14 patent families
  • The composition developed by Innocan research can be used to treat and prevent hair loss and is applied topically to the skin or scalp
  • The hair loss treatment products market is projected to grow to more than US$45 million by 2028
  • Innocan is a pharmaceutical technology company that focuses on the development of drug delivery platforms containing CBD
  • InnoCan Pharma Corporation opened trading at C$0.475 per share

Innocan Pharma (INNO) has filed a new patent application for a composition to treat and prevent hair loss.

The composition developed by Innocan (INNO) can be used to treat and prevent hair loss when applied topically to the skin or scalp.

The hair loss treatment products market was valued at almost US$16 million in 2020 and is projected to grow to more than US$45 million by 2028, representing a compound annual growth rate of 13.26 per cent between 2021 to 2028. 

This application contributes to Innocan’s expansion of its health and wellness intellectual property portfolio of 14 patent families.

Innocan CEO Iris Bincovich commented on the news.

“Innocan’s science is proving itself to have immense value in a variety of applications. We’re proud of our intellectual property as the backbone of our company and we are looking forward to the value that this activity will bring in the near term.”

Innocan is a pharmaceutical technology company that focuses on the development of drug delivery platforms containing Cannabidiol (CBD).

InnoCan Pharma Corporation opened trading at C$0.475 per share.


More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.

" Verano (CSE:VRNO) announces the opening of Zen Leaf Clarksburg

Verano Holdings (VRNO) has announced the opening of Zen Leaf Clarksburg, its fourth dispensary in West Virginia and 111th nationwide.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.